Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand

A prime-boost vaccination regimen with ALVAC-HIV (vCP1521) administered intramuscularly at 0, 4, 12, and 24 weeks and gp120 AIDSVAX B/E at 12 and 24 weeks demonstrated modest efficacy of 31.2% for prevention of HIV acquisition in HIV-uninfected adults participating in a community-based efficacy trial in Thailand.Reactogenicity was recorded for 3 days following vaccination. Adverse events were monitored every 6 months for 3.5 years, during which pregnancy outcomes were recorded. Of the 16,402 volunteers, 69% of the participants reported an adverse event any time after the first dose. Only 32.9% experienced an AE within 30 days following any vaccination. Overall adverse event rates and attribution of relatedness did not differ between groups. The frequency of serious adverse events was similar in vaccine (14.3%) and placebo (14.9%) recipients (p = 0.33). None of the 160 deaths (85 in vaccine and 75 in placebo recipients, p = 0.43) was assessed as related to vaccine. The most common cause of death was trauma or traffic accident. Approximately 30% of female participants reported a pregnancy during the study. Abnormal pregnancy outcomes were experienced in 17.1% of vaccine and 14.6% (p = 0.13) of placebo recipients. When the conception occurred within 3 months (estimated) of a vaccination, the majority of these abnormal outcomes were spontaneous or elective abortions among 22.2% and 15.3% of vaccine and placebo pregnant recipients, respectively (p = 0.08). Local reactions occurred in 88.0% of vaccine and 61.0% of placebo recipients (p<0.001) and were more frequent after ALVAC-HIV than AIDSVAX B/E vaccination. Systemic reactions were more frequent in vaccine than placebo recipients (77.2% vs. 59.8%, p<0.001). Local and systemic reactions were mostly mild to moderate, resolving within 3 days.The ALVAC-HIV and AIDSVAX B/E vaccine regimen was found to be safe, well tolerated and suitable for potential large-scale use in Thailand.ClinicalTrials.govNCT00223080

Achieving Collaborative Interaction with a Humanoid Robot

One of the great challenges of putting humanoid robots into space is developing cognitive capabilities for the robots with an interface that allows human astronauts to collaborate with the robots as naturally and efficiently as they would with other astronauts. In this joint effort with NASA and the entire Robonaut team we are integrating natural language and gesture understanding, spatial reasoning incorporating such features as human-robot perspective taking, and cognitive model-based understanding to achieve this high level of human-robot interaction

A task domain for combining and evaluating robotics and cognitive modeling techniques

Building systems that integrate different artificial intelligence techniques to achieve a higher level of total intelligence is very difficult. In order to build integrated systems, simplifying assumptions or abstractions are usually made when working in a specific domain. As a result of these assumptions and abstractions, the proper evaluation of integrated artificial intelligence techniques can be quite challenging. We suggest that the domain of hide and seek is a particularly well-suited task for integrating robotics and higher-level reasoning mechanisms such as computational cognitive modeling. Three different instantiations of integrated systems in the “hide and seek ” domain, which combine cognitive-level algorithms with lower level algorithms for perception and navigation are discussed